UNIVERSAL TECHNICAL INSTITUT (UTI) Stock Fundamental Analysis
NYSE:UTI • US9139151040
30.57 USD
-1.15 (-3.63%)
At close: Feb 20, 2026
30.57 USD
0 (0%)
After Hours: 2/20/2026, 8:09:03 PM
UTI gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 75 industry peers in the Diversified Consumer Services industry. While UTI belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. While showing a medium growth rate, UTI is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year UTI was profitable.
- In the past year UTI had a positive cash flow from operations.
- Each year in the past 5 years UTI has been profitable.
- In the past 5 years UTI always reported a positive cash flow from operatings.
1.2 Ratios
- Looking at the Return On Assets, with a value of 6.44%, UTI is in the better half of the industry, outperforming 72.00% of the companies in the same industry.
- The Return On Equity of UTI (15.98%) is better than 74.67% of its industry peers.
- UTI has a Return On Invested Capital of 8.69%. This is in the better half of the industry: UTI outperforms 76.00% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for UTI is below the industry average of 10.88%.
- The last Return On Invested Capital (8.69%) for UTI is above the 3 year average (7.27%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROIC | 8.69% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
1.3 Margins
- UTI has a Profit Margin of 6.28%. This is in the better half of the industry: UTI outperforms 65.33% of its industry peers.
- UTI's Profit Margin has improved in the last couple of years.
- UTI's Operating Margin of 8.38% is fine compared to the rest of the industry. UTI outperforms 65.33% of its industry peers.
- In the last couple of years the Operating Margin of UTI has grown nicely.
- With a Gross Margin value of 49.62%, UTI perfoms like the industry average, outperforming 54.67% of the companies in the same industry.
- In the last couple of years the Gross Margin of UTI has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% |
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), UTI is creating some value.
- The number of shares outstanding for UTI has been increased compared to 1 year ago.
- UTI has more shares outstanding than it did 5 years ago.
- UTI has a better debt/assets ratio than last year.
2.2 Solvency
- An Altman-Z score of 3.57 indicates that UTI is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.57, UTI belongs to the top of the industry, outperforming 82.67% of the companies in the same industry.
- The Debt to FCF ratio of UTI is 6.28, which is on the high side as it means it would take UTI, 6.28 years of fcf income to pay off all of its debts.
- With a decent Debt to FCF ratio value of 6.28, UTI is doing good in the industry, outperforming 73.33% of the companies in the same industry.
- UTI has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
- UTI has a Debt to Equity ratio (0.29) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Altman-Z | 3.57 |
ROIC/WACC1.03
WACC8.45%
2.3 Liquidity
- A Current Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI has a Current ratio (1.14) which is comparable to the rest of the industry.
- A Quick Ratio of 1.14 indicates that UTI should not have too much problems paying its short term obligations.
- UTI has a Quick ratio (1.14) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 |
3. Growth
3.1 Past
- The earnings per share for UTI have decreased by 0.00% in the last year.
- The Earnings Per Share has been growing by 65.96% on average over the past years. This is a very strong growth
- Looking at the last year, UTI shows a quite strong growth in Revenue. The Revenue has grown by 12.59% in the last year.
- UTI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 22.67% yearly.
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
3.2 Future
- Based on estimates for the next years, UTI will show a small growth in Earnings Per Share. The EPS will grow by 6.67% on average per year.
- The Revenue is expected to grow by 8.84% on average over the next years. This is quite good.
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3Y6.67%
EPS Next 5YN/A
Revenue Next Year9.49%
Revenue Next 2Y8.85%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 31.52, the valuation of UTI can be described as expensive.
- The rest of the industry has a similar Price/Earnings ratio as UTI.
- When comparing the Price/Earnings ratio of UTI to the average of the S&P500 Index (26.99), we can say UTI is valued inline with the index average.
- UTI is valuated quite expensively with a Price/Forward Earnings ratio of 34.25.
- UTI's Price/Forward Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Forward Earnings ratio of 28.02, UTI is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.52 | ||
| Fwd PE | 34.25 |
4.2 Price Multiples
- UTI's Enterprise Value to EBITDA ratio is in line with the industry average.
- Based on the Price/Free Cash Flow ratio, UTI is valued a bit cheaper than 61.33% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 104.22 | ||
| EV/EBITDA | 14.7 |
4.3 Compensation for Growth
- UTI has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.48
EPS Next 2Y-11.51%
EPS Next 3Y6.67%
5. Dividend
5.1 Amount
- No dividends for UTI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
30.57
-1.15 (-3.63%)
Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-04 2026-02-04/amc
Earnings (Next)05-05 2026-05-05
Inst Owners97.52%
Inst Owner Change7.25%
Ins Owners2.78%
Ins Owner Change4.84%
Market Cap1.68B
Revenue(TTM)855.03M
Net Income(TTM)53.69M
Analysts81.82
Price Target38.18 (24.89%)
Short Float %4.56%
Short Ratio3.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.03
Dividend Growth(5Y)-34.43%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.57%
Min EPS beat(2)28.91%
Max EPS beat(2)66.22%
EPS beat(4)4
Avg EPS beat(4)59.42%
Min EPS beat(4)28.91%
Max EPS beat(4)73.27%
EPS beat(8)7
Avg EPS beat(8)48.68%
EPS beat(12)11
Avg EPS beat(12)85.96%
EPS beat(16)14
Avg EPS beat(16)183.11%
Revenue beat(2)2
Avg Revenue beat(2)0.64%
Min Revenue beat(2)0.47%
Max Revenue beat(2)0.82%
Revenue beat(4)4
Avg Revenue beat(4)1.74%
Min Revenue beat(4)0.47%
Max Revenue beat(4)4.51%
Revenue beat(8)8
Avg Revenue beat(8)2.01%
Revenue beat(12)12
Avg Revenue beat(12)2.35%
Revenue beat(16)15
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-59.54%
EPS NQ rev (3m)-84.41%
EPS NY rev (1m)0%
EPS NY rev (3m)-16.43%
Revenue NQ rev (1m)-0.36%
Revenue NQ rev (3m)-0.03%
Revenue NY rev (1m)0.23%
Revenue NY rev (3m)1.15%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.52 | ||
| Fwd PE | 34.25 | ||
| P/S | 1.97 | ||
| P/FCF | 104.22 | ||
| P/OCF | 21.72 | ||
| P/B | 5.01 | ||
| P/tB | 5.87 | ||
| EV/EBITDA | 14.7 |
EPS(TTM)0.97
EY3.17%
EPS(NY)0.89
Fwd EY2.92%
FCF(TTM)0.29
FCFY0.96%
OCF(TTM)1.41
OCFY4.6%
SpS15.54
BVpS6.11
TBVpS5.21
PEG (NY)N/A
PEG (5Y)0.48
Graham Number11.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.44% | ||
| ROE | 15.98% | ||
| ROCE | 11.63% | ||
| ROIC | 8.69% | ||
| ROICexc | 11.82% | ||
| ROICexgc | 13.27% | ||
| OM | 8.38% | ||
| PM (TTM) | 6.28% | ||
| GM | 49.62% | ||
| FCFM | 1.89% |
ROA(3y)4.45%
ROA(5y)3.5%
ROE(3y)11.95%
ROE(5y)9.34%
ROIC(3y)7.27%
ROIC(5y)5.89%
ROICexc(3y)10.21%
ROICexc(5y)8.25%
ROICexgc(3y)11.54%
ROICexgc(5y)9.21%
ROCE(3y)9.72%
ROCE(5y)7.88%
ROICexgc growth 3Y34.26%
ROICexgc growth 5YN/A
ROICexc growth 3Y33.76%
ROICexc growth 5YN/A
OM growth 3Y17.03%
OM growth 5YN/A
PM growth 3Y35.13%
PM growth 5Y53.06%
GM growth 3Y-13.36%
GM growth 5Y-8.21%
F-Score7
Asset Turnover1.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | 6.28 | ||
| Debt/EBITDA | 0.93 | ||
| Cap/Depr | 181.06% | ||
| Cap/Sales | 7.17% | ||
| Interest Coverage | 13.88 | ||
| Cash Conversion | 73.39% | ||
| Profit Quality | 30.06% | ||
| Current Ratio | 1.14 | ||
| Quick Ratio | 1.14 | ||
| Altman-Z | 3.57 |
F-Score7
WACC8.45%
ROIC/WACC1.03
Cap/Depr(3y)145.01%
Cap/Depr(5y)268.95%
Cap/Sales(3y)5.89%
Cap/Sales(5y)11.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)0%
EPS 3Y3.11%
EPS 5Y65.96%
EPS Q2Q%-42.5%
EPS Next Y-31.68%
EPS Next 2Y-11.51%
EPS Next 3Y6.67%
EPS Next 5YN/A
Revenue 1Y (TTM)12.59%
Revenue growth 3Y25.89%
Revenue growth 5Y22.67%
Sales Q2Q%9.64%
Revenue Next Year9.49%
Revenue Next 2Y8.85%
Revenue Next 3Y8.84%
Revenue Next 5YN/A
EBIT growth 1Y-0.64%
EBIT growth 3Y47.33%
EBIT growth 5YN/A
EBIT Next Year46.16%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y371.76%
FCF growth 3YN/A
FCF growth 5Y99.08%
OCF growth 1Y35.47%
OCF growth 3Y28.35%
OCF growth 5Y54.57%
UNIVERSAL TECHNICAL INSTITUT / UTI FAQ
What is the fundamental rating for UTI stock?
ChartMill assigns a fundamental rating of 5 / 10 to UTI.
What is the valuation status for UTI stock?
ChartMill assigns a valuation rating of 3 / 10 to UNIVERSAL TECHNICAL INSTITUT (UTI). This can be considered as Overvalued.
Can you provide the profitability details for UNIVERSAL TECHNICAL INSTITUT?
UNIVERSAL TECHNICAL INSTITUT (UTI) has a profitability rating of 7 / 10.
Can you provide the financial health for UTI stock?
The financial health rating of UNIVERSAL TECHNICAL INSTITUT (UTI) is 5 / 10.
What is the earnings growth outlook for UNIVERSAL TECHNICAL INSTITUT?
The Earnings per Share (EPS) of UNIVERSAL TECHNICAL INSTITUT (UTI) is expected to decline by -31.68% in the next year.